Project Grant R61CA309704
Award Date 8/19/26
Completion Date 7/31/29
Dollars Obligated $237K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute awarded The Trustees of the University of Pennsylvania $434,969 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate type I interferon response and differentiation in FLT3-inhibitor persistent acute myeloid leukemia. The funded research develops genetically engineered mouse models of acute myeloid leukemia with inducible and reversible FLT3 mutations to understand cellular mechanisms that maintain FLT3-mutant clone persistence...
- The National Cancer Institute awarded The Children's Hospital Of Philadelphia $744,511 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize hematopoietic stem and progenitor cell-like (HSPC-like) blasts in high-risk acute leukemias and identify therapeutic vulnerabilities in these treatment-resistant leukemic populations. The research investigates molecular characteristics and clinical implications of HSPC-like blasts across major high-risk leukemia...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Missouri System $486,426 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to explore niche-leukemic stem cell interactions and evaluate niche-directed leukemia treatments. The research aims to unravel how minimal residual leukemic stem cells survive within the bone marrow microenvironment, called the niche, which drives therapeutic...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $668,864 on June 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development of a biomarker to predict patient response to chimeric antigen receptor (CAR) T cell therapy for glioblastoma and to identify mechanisms of tumor resistance to CAR T treatment. The research employs...
- The National Cancer Institute awarded The Leland Stanford Junior University $644,703 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing) to develop a human bone marrow organoid culture method that sustains both normal and leukemic hematopoiesis. The project addresses a historic inability to culture hematopoietic stem cells, progenitors, and leukemic blasts beyond days to weeks by recapitulating the structurally and cellularly complex...
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $703,071 on April 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define the determinants of long-term CAR-T cell persistence in blood cancer patients. The research identifies the cellular and molecular properties of CAR-T cells that sustain durable anti-tumor function years after infusion. Prior work by the investigative team revealed that long-lived CAR-T cells up to five years...
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $147,874 on August 13, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into the mechanisms of enhancer regulation by EBF1 in mantle cell lymphoma. The research will uncover how EBF1 influences three-dimensional genome organization in mantle cell lymphoma, a highly aggressive B-cell malignancy. The investigator will employ super-resolution microscopy and long-read sequencing...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $1.376 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) for Project Grant R01CA303022. The award funds development of optimized invariant natural killer T (iNKT) cell therapies engineered with chimeric antigen receptors (CARs) to treat solid tumors. The project pairs high-performing iNKT cell...
- The National Cancer Institute awarded the University of Pennsylvania $148,626 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) for a project investigating the role of N6-methyladenosine (m6A) modifications on mRNA during adaptive stress in prostate cancer. The funded work addresses drug resistance in prostate cancer by examining how the integrated stress response (ISR)—an adaptive cellular pathway triggered by cancer treatments and tumor microenvironment...
- The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...